Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568961 | 0.85 | PNMT (0.51) | PNMTOPRM1OPRL1KCNH2 | |
| SCHEMBL5568958 | 0.85 | PNMT (0.51) | PNMTOPRM1OPRL1KCNH2 | |
| SCHEMBL16879112 | 0.82 | PNMT (0.48) | PNMTLTA4HNR1D1 | |
| SCHEMBL16879115 | 0.82 | PNMT (0.48) | PNMTLTA4HNR1D1 | |
| SCHEMBL16889040 | 0.80 | LTA4H (0.40) | PNMTLTA4HOPRM1OPRL1KCNH2 | |
| SCHEMBL16878941 | 0.78 | LTA4H (0.39) | PNMTLTA4HOPRM1OPRL1KCNH2 | |
| SCHEMBL16878940 | 0.78 | LTA4H (0.39) | PNMTLTA4HOPRM1OPRL1KCNH2 | |
| SCHEMBL3119353 | 0.77 | PNMT (0.60) | PNMTOPRM1OPRL1KCNH2CXCR4 | |
| SCHEMBL16878923 | 0.77 | NR1D1 (0.46) | PNMTLTA4HOPRM1OPRL1KCNH2 | |
| SCHEMBL16878925 | 0.77 | NR1D1 (0.46) | PNMTLTA4HOPRM1OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | PNMT 2091/4885LTA4H 936/4885OPRM1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.